In particular, amplification and overexpression of CDK8 have been found in colon, breast, and prostate cancers [14, 16–18], which underlies the marked attention that CDK8 has attracted as a potential target for cancer therapy by small molecule inhibitors [19–21]. Here, CDK8 is linked to prostate carcinoma.